Arineta

Company Overview

Snapshot

Founded in June 2006 by Yosi Morik, Arineta operates with 51–200 employees. The company has raised $10 million across one disclosed funding round. In April 2025, Arineta engaged in discussions regarding a potential sale for $300 million.

Business overview

Arineta specializes in developing and producing cardiovascular imaging solutions, primarily serving the Health Tech & Life Sciences sector. Its core product, CardioGraphe, is a dedicated single-heartbeat, whole-heart cardiac CT scanner utilizing proprietary Stereo CT technology. This system provides comprehensive clinical information for diagnosis and therapy planning, optimized for imaging the entire heart and cardiovascular system with reduced radiation doses and contrast volumes. CardioGraphe is distributed globally by GE Healthcare and holds regulatory clearance in key markets including the United States, Canada, European Union, China, and Israel.

Strategic signal

In April 2025, Arineta was reportedly in discussions for a potential acquisition valued at $300 million. This indicates significant market validation for its cardiovascular imaging technology and suggests a strong potential for a strategic exit or major investment, signaling to investors a high-growth trajectory and a valuable intellectual property portfolio in the medical device sector.

Company Intelligence Q&A

What is Arineta's flagship product?

Arineta's flagship product is CardioGraphe, a dedicated single-heartbeat, whole-heart cardiac CT scanner based on the company's proprietary Stereo CT technology, designed for comprehensive cardiovascular imaging.

When did Arineta receive FDA clearance for its cardiology CT device?

In August 2016, Arineta received FDA clearance for its cardiology CT device, enabling its use in the United States market.

What significant order did GE place with Arineta?

In June 2017, GE ordered 12 CT systems from Arineta, highlighting a key partnership and market adoption for Arineta's imaging solutions.

What was the reported valuation for a potential sale of Arineta?

In April 2025, Arineta was reported to be in discussions for a potential sale with a valuation of $300 million.

Which major company distributes Arineta's CardioGraphe globally?

Arineta's CardioGraphe is distributed globally by GE Healthcare, expanding its reach into North America, Europe, China, and Israel.